Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase - A potential reason for resistance to Glivec in chronic myelogenous leukaemia

Biochemical Pharmacology

Volumn 66, Issue 10, 2003, Pages 1879-1884

  Bakalova, Rumiana ^a   Ohba, Hideki ^a,b   Zhelev, Zhivko ^b   Ishikawa, Mitsuru ^a   Shinohara, Yasuo ^a,c   Baba, Yoshinobu ^a,c  

^a AIST Shikoku   (Japan)

^b Natl Inst Adv Indust Sci T   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Bcr Abl tyrosine kinase; Chronic myelogenous leukaemia; Glivec; Protein kinase C; Telomerase

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; IMATINIB; PROTEIN KINASE C; TANKYRASE; TELOMERASE;

CELL GROWTH; CELL IMMORTALIZATION; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CHRONICITY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME REPRESSION; HUMAN; LEUKEMIA CELL; LONG TERM CARE; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0242266597     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.06.001     Document Type: Note

References (21)

1. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Nagesh-Rao P., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification. Science. 293:2001;876-880.
2. Von Bubnoff N., Schneller F., Peschel S., Duyster J. Bcr-Abl gene mutations in relation to clinical resistance of Philadelphia-chromosome- positive leukaemia to STI-571: a prospective study. Lancet. 359:2002;487-491.
3. Hofmann W.K., Jones L.C., Lemp N.A., de Vos S., Gschaidmeier H., Hoelzer D., Ottmann O.G., Koeffler H.P. Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI-571 has a unique Bcr-Abl gene mutation. Blood. 99:2002;1860-1862.
4. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., Herrmann R., Lynch K.P., Hughes T.P. High frequency of point mutations clustered within the adenosine triphosphate-binding region of Bcr/Abl in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 99:2002;3472-3475.
5. Capdeville R., Buchdunger E., Zimmermann J., Matter A. Glivec (STI-571, Imatinib), a rationally developed, targeted anticancer drug. Nature. 1:2002;493-502.
6. Ohayashiki K., Ohayashiki J.H., Iwata H., Hayashi S., Shay J.W., Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia. 11:1997;190-194.
7. Engelhardt M., Mackenzie K., Drullinsky P., Silver R.T., Moore M.A. Telomerase activity and telomere length in acute and chronic leukemia pre- and post-ex vivo culture. Cancer Res. 60:2000;610-617.
8. Ohyashiki K., Sashida G., Tauchi T., Ohyashiki K. Telomeres and telomerase in haematologic neoplasia. Oncogene. 21:2002;680-687.
9. Kang S.S., Kwon T., Kwon D.Y., Do S.I. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J. Biol. Chem. 274:1999;13085-13090.
10. Li H., Zhao L.L., Funder J.W., Liu J.-P. Telomerase is controlled by protein kinase C-alpha in human breast cancer cells. J. Biol. Chem. 273:1998;33436-33442.
11. Yu C.-C., Lo S.-C., Wang T.-C. Telomerase is regulated by protein kinase C-zeta in human nasopharyngeal cancer cells. Biochem. J. 355:2001;459-464.
12. Kharbanda S., Kumar V., Dhar S., Pandey P., Chen C., Majumder P., Yuan Z.M., Whang Y., Strauss W., Pandita T.K., Weaver D., Kufe D. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. Curr. Biol. 10:2000;568-575.
13. Bianchi A., Smith S., Chong L., Elias P., de Lange T. TRF1 is a dimer and bends telomeric DNA. EMBO J. 16:1997;1785-1794.
14. Ohyashiki J.H., Hayashi S., Yahata N., Iwama H., Ando K., Tauchi T., Ohyashiki K. Impaired telomere regulation mechanism by TRF1 (telomeric-binding protein) but not TRF2 expression in acute leukemia cells. Int. J. Oncol. 18:2001;593-598.
15. Cook B.D., Dynek J.N., Chang W., Shostak G., Smith S. Role of the related poly(ADP-ribose)polymerases tankyrase 1 and 2 at human telomeres. Mol. Cell Biol. 22:2002;332-342.
16. Smith S., de Lange T. Tankyrase promotes telomere elongation in human cells. Curr. Biol. 10:2000;1299-1302.
17. Teague S.J., Davis A.M., Leeson P.D., Oprea T. The design of leadlike combinatorial libraries. Angew Chem. Int. Ed. Engl. 38(24):1999;3743-3748.
18. Zimmermann J., Caravatti G., Mett H., Meyer T., Muller M., Lydon N.B., Fabbro D. Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PK-C). Arch. Pharm. (Weinheim). 329(7):1996;371-376.
19. Kano Y., Akutsu M., Tsunoda S., Mano H., Sato Y., Honma Y., Furukawa Y. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI-571 in combination with commonly used antileukemic agents. Blood. 97:2001;1999-2007.
20. Klejman A., Rushen L., Morrione A., Slupianek A., Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the antileukemia effect of STI-571. Oncogene. 21:2002;5868-5876.
21. Tauchi T., Nakajima A., Sashida G., Shimamoto T., Ohyashiki J.H., Abe K., Yamamoto K., Ohyashiki K. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor Imatinib, in Bcr-Abl-positive leukemia cells. Clin. Cancer Res. 8:2002;3341-3347.